If you've been looking into Wegovy semaglutide tablets as a needle-free weight loss treatment option, you've probably wondered how much they'll cost in the UK.
Wegovy semaglutide tablets were approved by the MHRA on 11 June 2026. As of the approval date, Novo Nordisk has not yet published a UK list price - that will follow the commercial launch, which the company expects to happen within weeks. This guide covers what we know about expected UK pricing based on international benchmarks, how the tablet compares to the injection on cost, and what your options are right now.
Is Wegovy Available as a Tablet in the UK?
Yes, as of 11 June 2026. Wegovy semaglutide tablets were approved by the MHRA on that date, making the UK the first country in Europe to license an oral GLP-1 for weight management. Novo Nordisk expects private prescription availability to follow within weeks of approval. NHS access will require a separate NICE cost-effectiveness review and is not expected before 2027.
It's worth clarifying a common source of confusion. Rybelsus is an oral semaglutide tablet that is already available in the UK, but it's licensed only for type 2 diabetes at doses up to 14mg. The Wegovy tablet is a different, higher-dose product formulated specifically for weight management, at 25mg, and is being assessed by the MHRA for that licensed use.
How Much Will Wegovy Semaglutide Tablets Cost in the UK?
No confirmed UK price has been announced yet. The MHRA granted marketing authorisation on 11 June 2026, and Novo Nordisk has indicated the tablet will be available by private prescription within weeks. A UK list price is expected to be published around that commercial launch date.
The most useful reference point is the US launch pricing. The Wegovy pill launched in the United States in January 2026 through Novo Nordisk's NovoCare Pharmacy programme. Self-pay pricing starts at around $149 per month for the lowest doses, rising to $299 per month for the maintenance dose of 25mg.1
Converting those figures at current exchange rates, the lower doses would sit at approximately £110 to £120 per month, with the maintenance dose in the region of £220 to £230 per month. These are indicative figures only. UK prices tend to reflect local manufacturing costs, distribution, and healthcare market dynamics, so the actual price at UK pharmacies may differ in either direction.
In the US, the Wegovy injection carries a list price of over $1,300 per month without insurance, while the tablet launched at $299 for the maintenance dose. Whether a similar relationship holds in the UK remains to be seen, but it's an encouraging signal for patients who prefer an oral option.
How Does the Expected Cost Compare to the Wegovy Injection?
If UK tablet pricing follows a similar pattern to the US launch, the oral semaglutide maintenance dose could land in a comparable range to the injection, or potentially slightly below. The titration journey is also similar in structure. Both formulations begin at a lower starting dose and escalate over several months, so the cost in the early stages of treatment is likely to be lower than at maintenance.
There's one meaningful difference in clinical outcomes to bear in mind. In the OASIS 4 trial, published in the New England Journal of Medicine, participants taking oral semaglutide 25mg once daily lost an average of 13.6% of their body weight over 64 weeks in the treatment-policy analysis.1 With full treatment adherence, mean weight loss reached 16.6%.1 The Wegovy injection (semaglutide 2.4mg weekly) has demonstrated average weight loss of around 15 to 17% in clinical trials,2 meaning the two formulations produce broadly comparable outcomes, with some individual variation.
If cost is a primary factor, both options are likely to sit in a similar monthly price range once the tablet becomes available in the UK. The choice between them will depend more on personal preference, dosing schedule, and clinical suitability than on price alone.
Will Wegovy Semaglutide Tablets Be Available on the NHS?
NHS coverage for the Wegovy tablet, if approved, would require a separate assessment by NICE for cost-effectiveness in the NHS setting. This process typically takes several months to complete after MHRA approval.4 Given that the current Wegovy injection only received NHS approval for specialist weight management services in 2023, and access remains limited, NHS availability for the oral tablet before 2027 is considered unlikely by most industry observers.
In Scotland, Wales, and Northern Ireland, prescribing guidance is issued by the respective bodies (SMC, AWMSG, and NICPLD), which conduct their own assessments independently of NICE.
For patients who meet NHS eligibility criteria and are currently on a waiting list through a specialist weight management service, it's worth discussing with your clinician whether the tablet, once approved, would be an appropriate alternative to the injection.
What Weight Loss Tablet Options Are Available Now?
While the Wegovy tablet awaits MHRA approval, two oral weight loss options are available in the UK.
Orlistat
Orlistat is a licensed oral weight loss medicine that works by blocking around a third of the fat absorbed from food. It's taken three times daily with meals and is available on the NHS for eligible patients. Unlike semaglutide-based treatments, it doesn't act on appetite or GLP-1 pathways. Instead, it reduces the calories your body absorbs from dietary fat. It's one of the most established oral weight loss medicines available in the UK.
Rybelsus (Oral Semaglutide)
Rybelsus is an oral semaglutide tablet licensed in the UK for type 2 diabetes. While it's not licensed for weight management, some patients prescribed it for diabetes may notice weight loss as a secondary effect. It's not available for weight loss on its own in the UK and should not be sought for this purpose outside its licensed indication.
Wegovy Injection
The Wegovy injectable pen is the MHRA-approved semaglutide option currently available for weight management in the UK. It contains the same active ingredient as the upcoming oral tablet and delivers comparable clinical outcomes. For patients who want to begin semaglutide treatment now rather than waiting for the tablet, the injection is the appropriate route.
How to Be Notified When Wegovy Tablets Are Available in the UK
Wegovy semaglutide tablets are now MHRA-approved and expected to be available by private prescription within weeks. Visit our Wegovy oral tablet page for the latest availability updates. In the meantime, if you're eligible and ready to start treatment now, our clinical team can assess your suitability for the Wegovy injection or other available options.
When to Seek Medical Advice
Whether you are considering the Wegovy tablet, the Wegovy injection, or any other prescription weight loss treatment, a clinical assessment is the right starting point. A clinician will review your BMI, health history, and current medications before recommending a treatment and dose. Self-prescribing or purchasing semaglutide from unregulated sources carries significant safety risks and isn't advisable.
Contact your GP or a registered prescribing clinician if you:
- Have a history of pancreatitis, thyroid conditions, or a personal or family history of medullary thyroid carcinoma
- Are pregnant, planning to become pregnant, or breastfeeding
- Are taking other medications that may interact with semaglutide
- Are already using another semaglutide-containing product, such as Ozempic or Rybelsus
Frequently Asked Questions
How much will Wegovy semaglutide tablets cost in the UK?
No official UK price has been confirmed yet. The MHRA approved the tablet on 11 June 2026, and a UK list price is expected to be published when it commercially launches, which Novo Nordisk anticipates will be within weeks. Based on US launch pricing, the maintenance dose is expected to cost in the region of £220–£230 per month at private pharmacies, with lower starting doses likely costing less.
When will Wegovy tablets be available in the UK?
Wegovy semaglutide tablets were approved by the MHRA on 11 June 2026. Novo Nordisk expects the tablet to be available by private prescription within weeks of that decision. NHS access requires a separate NICE appraisal and is not expected before 2027.
Will Wegovy semaglutide tablets be cheaper than the injection?
Possibly. In the US, the Wegovy tablet launched at a significantly lower price than the injectable version. Whether that pattern holds in the UK is not yet confirmed, but the two formulations are expected to sit in a broadly comparable monthly price range.
Are Wegovy tablets available on the NHS?
Not yet, and they are not expected to be before 2027 at the earliest. Even after MHRA approval, a separate NICE cost-effectiveness review would be required before NHS prescribing guidance could be issued.
What is the difference between Wegovy tablets and Rybelsus?
Both are oral semaglutide tablets, but they are different products. Rybelsus is licensed in the UK for type 2 diabetes at doses up to 14mg. The Wegovy tablet is a higher-dose formulation (25mg) developed specifically for weight management and is not yet approved in the UK.
How effective are Wegovy semaglutide tablets for weight loss?
In the Phase 3 OASIS 4 trial, participants taking oral semaglutide 25mg once daily lost an average of 13.6% of their body weight over 64 weeks. With full treatment adherence, mean weight loss reached 16.6%. Around one in three participants achieved 20% or more weight loss.
What oral weight loss tablets are available in the UK right now?
Orlistat is the main licensed oral weight loss medicine currently available in the UK, and it can be prescribed on the NHS for eligible patients. The Wegovy injection is also available by private prescription for those who want to start semaglutide treatment now.
Can I use Rybelsus for weight loss in the UK?
No. Rybelsus is licensed in the UK only for managing blood sugar in adults with type 2 diabetes. It's not licensed for weight management and should not be sought for that purpose outside its approved indication.
References
- Wharton S, et al. Oral Semaglutide 25 mg Once Daily for Obesity (OASIS 4): a randomised, double-blind, placebo-controlled, phase 3 trial. New England Journal of Medicine. 2025. doi:10.1056/NEJMoa2500583
- Novo Nordisk Ltd. Wegovy (semaglutide) 2.4mg Summary of Product Characteristics. Electronic Medicines Compendium (eMC). medicines.org.uk/emc/product/13795/smpc
- Medicines and Healthcare products Regulatory Agency (MHRA). New drug authorisations and licences. gov.uk/mhra
- National Institute for Health and Care Excellence (NICE). Semaglutide for managing overweight and obesity. Technology appraisal guidance TA875. 2023. nice.org.uk/ta875
This article is intended for informational purposes only and does not replace professional medical advice. All pricing information is indicative based on publicly available data at the time of writing and is subject to change. Always speak to a registered healthcare professional before starting any prescription medicine.